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The advent of the genetics era has profoundly changed the way we look at iron related diseases, particularly hemochromatosis. New
discoveries have challenged historical concepts about the disease, such as its monogenic nature, intestinal origin or complete phenotypic
penetrance. This review presents a new concept of hemochromatosis which stems from the idea that, beyond their genetic diversities, all known
hemochromatoses have in common the same metabolic abnormality: the genetically determined failure to prevent unneeded iron from entering the
circulatory pool. Inappropriate levels of hepcidin, the iron hormone, appear now as the central pathogenic event in all forms of hemochromatosis:
depending on the protein involved, and its effect on hepatic production of hepcidin, the phenotype varies, ranging from massive early-onset iron
loading with severe organ disease (e.g., associated with homozygous mutations of hemojuvelin or hepcidin itself) to the milder late-onset
phenotype characterizing the classic and highly prevalent HFE-related form or the rare transferrin receptor 2-related form. In vitro and in vivo
studies will be needed to dissect the consequences of each hereditary hemochromatosis allele and increase our understanding of the precise
contribution of each gene to the hereditary hemochromatosis phenotype.
© 2006 Elsevier B.V. All rights reserved.Keywords: Iron overload; HFE; Hepcidin; Ferroportin; Hemojuvelin; Transferrin receptor 2In 1889, Von Recklinghausen [1], a German pathologist,
used the term “hemochromatosis” to describe the necroscopic
finding of massive organ damage associated with dark tissue
staining with what he believed to be a blood-borne pigment. We
assume he was describing cases of “bronze diabetes”, a syn-
drome described a few decades earlier in France [2,3]. For years
this syndrome was ascribed to alcohol toxicity, at least until
Sheldon, in his monumental 1935 review of all cases published
in the world's medical literature [4], suggested its “hereditary”
nature. In fact, in 1996, it was triumphantly announced that a
pathogenic mutation (C282Y) involving the product of a novel
MHC class I-like gene, HFE, was present in the majority of
“hereditary hemochromatosis” patients throughout the world
[5]. However, as genetic testing for HFE mutations became
more widespread, it rapidly became clear that the situation was
more complicated than previously thought. Despite its remark-
ably high prevalence (approximately 5/1000 individuals of
northern European descent) [6], C282Y homozygosity was⁎ Tel.: +39 059 4222714; fax: +39 059 4224363.
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doi:10.1016/j.bbamcr.2006.05.013found to be characterized by low penetrance. Carriers are
genetically predisposed to a chain of events that may (or may
not) culminate in the severe and multiple organ damage seen by
Von Recklinghausen and Sheldon, but it is currently impossible
to predict whether and to what extent this risk will be expressed
[7]. To further complicate matters, other iron genes were iden-
tified whose mutations were associated with hereditary iron
overload syndromes with some, or many, or apparently even all
of the phenotypic features of classic hemochromatosis: trans-
ferrin receptor 2 [8] (TfR2), hepcidin [9,10] (HAMP),
hemojuvelin (HJV) [9,10] and ferroportin [11,12] (FPN). Is
the hemochromatosis label valid for these syndromes as well?
The OMIM database thinks so, and subcategorizes hemochro-
mathosis in “types” based mainly on chronological description
[13]: type 1, which is the classic form due to HFE mutations;
type 2, which actually comprises subtypes 2A (due to HAMP
mutations) and 2B (due to HJV mutations); type 3 (caused by
TfR2 mutations); and type 4 (due to FPN mutations). One of the
inconsistencies of this classification is that, while the pheno-
typic similarities between the juvenile-onset forms caused by
monogenic defects of HAMP or HJV are reflected in their
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associated with mutation of HFE or TfR2 appear as separate
types (respectively type 1 and type 3), with no indication
whatsoever of the phenotypic features they share. Furthermore,
this approach leaves no space for atypical cases related to
multiple gene mutations [14], or cases of juvenile hemochro-
matosis without HAMP or HJV mutations but with combined
mutations of HFE and TfR2 [15]. And last but not least, the
disorder listed as type IV hemochromatosis, otherwise known
as ferroportin disease [16] is clearly different from classic
hemochromatosis (and the other three types as well) in a number
of important respects (see below). Defining and classifying a
disease is not just a semantic or taxonomic exercise. Ideally, a
specific disease's or syndrome's name should unequivocally
identify a pathologic entity with unique pathophysiologic,
diagnostic and therapeutic features, be simple for students to
remind and useful to physicians for suspecting, identifying and
curing that disorder. In the case of genetic diseases, should
therefore a disease name invariably refer to a “unique” causative
gene or it may incorporate “many” pathogenic genes if they all
point to the same pathogenic pathway and cause the same
syndrome? This review presents a concept of hemochromatosis,
based on this new knowledge, which stems from the fact that,
beyond their genetic diversities, all known hemochromatoses,
belong to the same clinicopathologic entity, since they all
originate from the same pathophysiologic event: the genetic
disruption of the human tendency for circulatory iron constancy
caused by the failure to prevent unneeded iron from entering the
bloodstream.
1. The metabolic abnormality of hemochromatosis
Iron is relatively difficult to absorb from the diet, and only
about 10% of dietary iron (approximately 1 mg) is absorbed. In
the blood of humans and related mammals, concentration of
iron remains quite constant in the normal state as the priority is
to satisfy erythropoietic needs by delivering 20 mg iron on a
daily basis for incorporation into hemoglobin (Fig. 1A). Iron
stores have a wider variation: hepatic iron can range from
300 mg in a menstruated female to 1 g in an adult male, but can
reach 25–30 g in a patient with hemochromatosis. This is due to
the fact that the excretion of iron is very limited, making it
difficult for the organism to rid itself of an excess, except by
bleeding. The only regulated step of iron metabolism is in fact at
the level of intestinal iron absorption and excess iron entering
the body is efficiently stored in the liver [17].
The first biochemical manifestation of all forms of hemo-
chromatosis is an increase in the transferrin saturation, which
largely reflects an uncontrolled influx of iron into the blood-
stream from enterocytes and macrophages (Fig. 1B). Duodenal
transfer of iron to the plasma is inappropriately high for body
iron stores in hemochromatosis patients [18]. As a result, their
intestinal iron absorption generally exceeds iron loss by ap-
proximately 3 mg/day [19]. In normal subjects, phlebotomy trig-
gers sharp transient increases in absorption (from 1–2 mg/day to
5mg/day), mainly to ensure bone-marrow supplies. In hemochro-
matosis patients, this response is exaggerated (8–10 mg/day) andprolonged, sometimes lasting for years [20]. The enhanced ab-
sorption of dietary iron by duodenal enterocytes plays an essential
role in elevating total body iron, butmacrophages are normally the
source of most of the iron found in the plasma compartment [21].
In hemochromatosis, these cells seem to release more iron than
their normal counterparts, and consequently they are invariably
iron-poor [7]. What is the basis for the disruption of the genetic
control over the circulatory iron pool in hemochromatosis?
2. The pathogenic defect of HC
The rate at which iron enters the circulatory iron pool is
largely under the control of the hepcidin–ferroportin axis. The
release of iron from both duodenal cells and macrophages,
which is mediated by the iron exporter ferroportin (FPN), is in
fact normally down-regulated by the hepatic iron-regulating
hormone, hepcidin.
2.1. Hepcidin: the iron-hormone
Hepcidin is an antimicrobial peptide produced by hepatocytes in
response to inflammatory stimuli and iron [22–24]. Due to
significant antibacterial and antifungal activities of the C-terminal
peptide, hepcidin has been classified as a member of the cysteine-
rich, cationic, antimicrobial peptides, including the thionins and
defensins. It is the product of the HAMP gene, constituted of 3
exons and 2 introns located on chromosome 7 and 19 in mouse and
humans, respectively. Expression of hepcidin mRNA is nearly
confined to the liver. Evidence from transgenic mouse models
indicates that hepcidin is the principal down-regulator of the
transport of iron across the small intestine and the placenta, and its
release from macrophages. Mice with genetic disruption of either
the Upstream Stimulatory Factor 2 (USF2), which fail to express
either copy of the duplicated hepcidin genes immediately down-
stream of USF2 [25], or C-EBPa [26], required for hepcidin
transcriptional control, develop iron overload resembling hemo-
chromatosis. Transgenic animals over-expressing hepcidin die pe-
rinatally due to severe iron-deficiency anemia occurring in the
context of reticuloendothelial cell iron overload [27]. In vivo in-
jection of hepcidin intomice causes hypoferremia [28] and reduced
mucosal iron uptake and transfer to the carcass, independently on
iron status or presence of HFE [29]. The present view is that
hepcidin down-regulates iron efflux from intestine and macro-
phages by interacting with the main iron export protein in mam-
mals, ferroportin (FPN).
2.2. Ferroportin: the effector
Ferroportin1/IREG1/MTP1, the product of the SLC40A1
gene, was independently identified in 2000 by three different
laboratories and was shown to play a role in export iron in frog
oocytes and in cell lines [30–32]. It is a multi-domain trans-
membrane protein expressed in cells that play critical roles in
mammalian iron metabolism, including placental syncytiotro-
phoblasts, duodenal enterocytes, hepatocytes and RE macro-
phages. In human intestine, is highly expressed in conditions of
enhanced iron absorption, such as anemia and hemochromatosis
Fig. 1. Iron homeostasis in humans and its derangement in hemochromatosis. (A) Plasma levels of iron are closely regulated to ensure a daily supply of approximately
20 mg to the bone marrow for incorporation into hemoglobin in erythroid precursors and mature red cells. Most iron found in the plasma derives from the continuous
breakdown of hemoglobin in senescent red cells by reticuloendothelial macrophages. Approximately 1–2 mg/day is also taken up by duodenal enterocytes to
compensate for daily losses and transferred to the plasma compartment (absorbed) or, depending on body needs, stored in the cell as ferritin. Iron recycled by
macrophages (and that absorbed from the gut) is loaded onto serum transferrin and delivered primarily to bone marrow for re-incorporation into new red cell
precursors. The remaining body iron (approximately 1000 mg) is stored primarily in hepatocytes. (B) In hemochromatosis, the failure to keep out unneeded iron from
the circulatory pool is due to the uncontrolled, genetically determined, release of iron from enterocytes and macrophages. This leads to progressive expansion of this
pool of iron and sooner or later to parenchymal cell iron overload, particularly in the liver, hearth and endocrine glands. Depending of the affected gene and its role in
iron homeostasis, the extent and rapidity of circulatory iron expansion as well as organ toxicity may vary.
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stimuli [32,33,35–37]. The mRNA possesses an iron-respon-
sive element (IRE) in the 5′ untranslated region (UTR) that
binds iron regulatory proteins and may confer iron-dependent
regulation. In fact, FPN promoter is responsive to iron in
HepG2 and CaCO2 cells: deletion of various promoter frag-
ments do not abrogate iron-dependent regulation, while removal
of the IRE element leads to loss of iron control [38]. In vivo,
additional mechanisms may be important in controlling FPN
expression, particularly in the duodenum, in response to stimuli
such as hypoxia or erythron demands [39].
2.3. The hepcidin–ferroportin axis
It has been recently shown that hepcidin binds to FPN in
cultured cells stably expressing FPN, and, following complex
internalization, leads to FPN degradation [40] thereby inducing
reduced iron export. The hepcidin N-terminus seems to be
critical for interaction with FPN [41]. This model implies de-
creased FPN expression, and reduced iron egress from cells
such as enterocytes and macrophages, whenever circulating
hepcidin levels are high, namely, inflammation and iron over-
load. While the details of hepcidin response to inflammation
have been largely clarified, and the key role exerted by inflam-
matory cytokines, such as IL-1 and particularly IL-6, uni-
versally accepted [24,42–45], the basis for hepcidin activation
in response to circulatory iron is far from being understood. A
correlation between hepcidin expression and hepatic iron stores
or serum ferritin had been found in humans [43,46,47]. Yet,
exposure of cultured murine and human hepatocytes to ferric
iron [24] or iron-saturated transferrin [43] does not increasehepcidin mRNA and may even reduce it. This has led to suggest
that in vivo iron-sensing for hepcidin upregulation may take
place in other cell types, possibly Kupffer cells [48], but recent
studies have challenged this hypothesis [49,50]. Circumstantial
evidence seems to indicate that three protein, HFE, TfR2 and,
particularly, HJV, might be involved in iron-sensing.
2.4. HFE, TfR2 and Hemojuvelin: the hepcidin iron-sensors?
HFE is a major histocompatibility class-I-like protein whose
ancestral peptide-binding groove is too narrow to allow classic
antigen presentation [51] while a possible non-classic immu-
nological activity has been recently proposed [52]. It is
incapable of binding iron [53]. Interaction between HFE and
the transferrin receptor, TfR1, which mediates transferrin-bound
iron uptake by most cells [53,54], has been fully documented
although its biological effects are still uncertain. Moreover, it is
has been recently questioned that the interaction of HFE with
TfR1 might be important for the pathogenesis of hemochroma-
tosis [55–57]. The C282Y mutation (a single-base transition
leading to substitution of tyrosine for cysteine at position 282),
the most common pathogenic mutation of HFE, is associated
with disruption of a disulfide bond in HFE that is critical for its
binding to β2-microglobulin [58]. The latter interaction is nec-
essary for the stabilization, [intracytoplasmic] transport and
expression of HFE on the cell surface and endosomal mem-
branes where HFE interacts with TfR1. The H63D mutation, a
common HFE mutation whose pathogenic significance is still
uncertain, does not impair HFE-TfR1 interaction.
In 1999, the gene for a second human transferrin receptor
(TfR2) was cloned [59]. Unlike TfR1, the new receptor was
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by intracellular iron status [60]. TfR2 mediates the uptake of
transferrin-bound iron by hepatocytes [59], possibly through the
mechanism of receptor-mediated endocytosis similar to that
described for TfR1, but its in vitro affinity for transferrin is 25–
30-fold lower than that of TfR1 [61]. Yet, TfR2-mediated
transferrin-iron uptake may be of importance in hepatocytes,
which express a low number of TfR1. In vitro studies with
soluble recombinant forms of TFR2 and HFE have revealed no
direct interaction between the two [60]. The biologic role and
function of TFR2 remain unknown.
Hemojuvelin is transcribed from a gene of 4,265 bp into a full-
length transcript with five spliced isoforms [10]. The putative
full-length protein is 426 amino acids; it contains a C-terminal
GPI-anchor, suggesting that it can be present in either a soluble or
a cell-associated form. The function of hemojuvelin is presently
unknown. However, hepcidin levels are depressed in individuals
withHJVmutations, [10] and in HJV knock-out mice [62,63] and
a recent study in vitro suggests that HJV is a transcriptional
regulator of hepcidin [64] (see below). In this study it was shown
that cellular hemojuvelin positively regulated hepcidin mRNA
expression, and that recombinant soluble hemojuvelin suppressed
hepcidin mRNA expression in primary human hepatocytes in a
log-linear dose-dependent manner, suggesting binding competi-
tion between soluble and cell-associated hemojuvelin. The Au.
proposes that soluble and cell-associated hemojuvelin recipro-
cally regulate hepcidin expression in response to changes in
extracellular iron concentration.
A recent study points now to a transcription factor, SMAD4,
which might be directly responsible for hepcidin regulation in
the hepatocytes in response to iron and inflammatory stimuli
and whose genetic disruption leads to systemic iron overload in
mice [65].
2.5. The common pathogenic basis for hemochromatosis
The iron-overload syndromes associated with HFE, TfR2,
HAMP, and HJV mutations are all characterized by inadequate
hepcidin synthesis [10,15,47,66]. HAMP expression in the liver
is also significantly impaired in HFE, TfR2 and HJV knock-out
mice [62,67,68] and hepatic deposition of iron in HFE-KO
animals can be prevented by hepcidin overexpression [69].
These findings suggests a unifying pathogenic model for all
forms of hemochromatosis in which HFE, TfR2 and HJVare all
independent but complimentary regulators of hepcidin synthesis
in the liver (Fig. 2). It may be that circulatory iron is sensed by
hepcidin gene through the activity of HFE involved in TfR1
cycle and TfR2, while soluble HJV may also serve as an iron-
sensitive signal for hepcidin transcription. When all three
proteins function correctly (and the HAMP gene that encodes
hepcidin is normal), the amount of iron transferred into the
blood will be appropriate to body needs, and excessive iron
deposition in tissues will be avoided. The relative contributions
of the three genes to this modulatory process may be different,
with a more substantial role assigned to HJV based on the more
severe iron overload phenotype associated with HJV mutations.
Loss of one of the minor regulatory proteins (HFE- or TfR2-related hemochromatosis) will result in an appreciable increase
in iron influx into the bloodstream, but residual hepcidin
activity will be sustained by the second minor regulator and the
major regulator, HJV gene. The result is a mild “adult” hemo-
chromatosis phenotype, with gradual plasma iron loading and
gradual accumulation of iron in tissues (Fig. 2B and C). Loss of
the “major” hepcidin regulator, HJV will produced a more
dramatic effect on influx of iron into the bloodstream and result
in a more severe, “juvenile”, hemochromatosis (Fig. 2D).
Combined loss of HFE and TfR2 (HFE+TfR2-related HH)
would theoretically result in much more rapid and substantial
increases in plasma iron, and, consequently, greater iron over-
load in tissues: in short, a severe “juvenile” phenotype. In fact, a
recent study has described patients with juvenile hemochroma-
tosis associated with combined mutations of HFE and TfR2
[15]. Finally, the complete loss of hepcidin (HAMP-related
HH), in spite of normal HFE, TfR2, and HJV, will inevitably
lead to massive uncontrolled release of iron into the circulation
(Fig. 2E). In the presence of functioning FPN-mediated iron
export machinery in target cells, the deficient production of
hepcidin causes a situation resembling a tap that cannot be
turned off. Intestinal cells and macrophages continue to release
unneeded iron, depleting the stores in these cellular compart-
ments and overloading the circulatory pool. This will be
inevitably followed by iron accumulation in parenchymatous
organs.
3. A new definition and classification for hemochromatosis
In view of the genetic and pathogenic considerations
discussed above, Hemochromatosis or Hereditary Hemochro-
matosis should be defined today as an hereditary iron loading
disorder, multigenic in nature, caused by a genetically de-
termined failure to prevent unneeded iron from entering the
circulatory pool and characterized by progressive parenchymal
iron overload with potential for multi organ damage and dis-
ease. This definition embraces the classic disorder related to
HFE C282Y homozygosity (the prototype for this syndrome
and by far the most common form) and the rare disorders more
recently attributed to loss of TfR2, HAMP, or HJV (Table 1).
There exist four basic features that defines this disease. First,
its hereditary nature. The genetic forms recognized thus far
(those related to HFE, TfR2, HAMP, or HJV) are all
characterized by autosomal recessive inheritance. However,
the list of genes whose mutations can cause hemochromatosis
is destined to grow as our knowledge of human iron
metabolism increases, and the possibility of other patterns of
inheritance cannot be excluded. Second, iron overload initially
involving the plasma compartment. As discussed, in the
presence of functioning FPN-mediated iron export machinery
in target cells, the deficient production of hepcidin causes a
situation resembling a tap that cannot be turned off. Intestinal
cells and macrophages continue to release unneeded iron,
depleting the stores in these cellular compartments and
overloading the circulatory pool. Third, iron overload subse-
quently involving parenchymal cells. Apart from menstruation,
the body has no effective means of significantly reducing the
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tion in the parenchymal cells of key organs. Therefore, without
therapeutic intervention, there is a distinct risk that, sooner or
later, tissue iron overload will occur. The deposits, at variance
with the pattern of iron accumulation in transfusional siderosis,
are particularly evident in hepatocytes but may also be found
in parenchymal cells of the endocrine glands and heart. This
stage is reflected in increasing serum ferritin levels. The time
of onset and pattern of organ involvement vary depending on
the time-course and magnitude of the plasma iron overload,
which are, in turn, related to the underlying mutation. This is
the basis for the distinction that is commonly made between
the milder adult-onset syndromes (HFE- and TfR2-related) and
the more severe juvenile-onset forms (HJV- and HAMP-
related) [7]. The implied dichotomy is misleading: these forms
are merely two points on a phenotypic continuum. The
underlying syndrome is the same, as identical are the targets of
iron toxicity: liver, heart and endocrine glands. The earlier
onset of hypogonadism or cardiopathy in the “juvenile” as
compared to the “adult” forms is simply related to the rapidity
and extent of massive circulatory and tissue iron load due to
marked hepcidin loss and suggests that endocrine organs and
heart have a particular susceptibility to iron toxicity. Rapid
iron accumulation in these organs may be less tolerated than in
the liver, which is physiologically more protected against iron
toxicity. Fourth, unimpaired erythropoiesis—iron is abundant
(even excessive) in the plasma, and its transport to the bone
marrow by transferrin and incorporation into hemoglobin are
unaffected by the genetic defects that cause hemochromatosis.
Consequently, anemia is not a feature of this iron-overload
syndrome, and therapeutic phlebotomy is tolerated quite well.
If hemochromatosis is defined by the presence of all four of
the features discussed above, other iron-overload syndromes
can be excluded from this subset if they lack at least one of its
defining characteristics (Table 2).
4. The epidemiologic and clinical impact of
hemochromatosis
HFE-related hemochromatosis is the most common form of
hemochromatosis and also the most frequently inherited
metabolic disorder found in whites, with a prevalence of the
pathogenic mutation ten times higher than that of cystic
fibrosis. HFE-hemochromatosis is an excellent illustration of
the “founder effect,” according to which a genetic disease can
arise from a chance mutation occurring in a single individual,
in this case a Celtic or Viking ancestor inhabiting northwestern
Europe. The genetic defect, which caused no serious obstacleFig. 2. The hepcidin–ferroportin functional axis in the control of circulatory iron and
by the liver modulates the extent and rate of iron release from macrophages and entero
to the circulatory iron signal. Lack of one of the hepcidin regulators will lead to unrest
expansion of the plasma iron pool, tissue iron overload and organ damage (see text
expression, the extent of circulatory iron overload will be marginal (HFE-hemoc
hemochromatosis, panel D). Complete loss of hepcidin (HAMP-hemochromatosis, pa
that occurring during loss of the main hepcidin regulator, HJV. When the genetic defe
egress from cells, particularly macrophages, will cause tissue iron overload (retention
ferroportin disease (panel F).to reproduction and may even have conferred some advan-
tages, was passed on and spread through population migration.
The distribution of the C282Y mutation coincides with its
northern European origin and with the presence of the disease
[70].
HFE-related hemochromatosis is a multifactorial disease
characterized by step-wise progression from biochemical ab-
normality to organ toxicity. The altered HFE protein plays an
essential role in this process but its presence alone is insufficient
to explain the broad spectrum of metabolic and pathologic
consequences ascribed to the disease [7]. In this context, it is
likely that many factors, host-related (age, gender, modifier
genes) or acquired (diet, alcohol abuse) exert an important role
on phenotypic penetrance of the genetic defect [7]. Expressivity
of the genetic defect may in fact lead to biochemical abnor-
malities, symptoms and signs or overt organ disease. Early
diagnosis in hemochromatosis is especially important since
treatment by venesection before irreversible end-organ damage
has occurred can restore a normal life expectancy. It is currently
impossible to predict whether (and to what extent) a C282Y
homozygote will express the disease phenotype. At present, we
can only conclude that, while the majority of C282Y homo-
zygotes have laboratory evidence of plasma and tissue iron
overload (i.e., high transferrin saturation and ferritin levels,
respectively), organ disease requiring medical treatment is
today much less common [7,71].
The clinical impact of the H63D mutation on the second
HFE allele appears to be limited [72], and yet, 1%–2% of
compound C282Y/H63D heterozygotes seem to be predisposed
to expression of the disease [70].
The frequency of TfR2 mutations is low and so far they
have been detected in a few pedigrees throughout the world,
and TfR2 mutations do not appear to be restricted to Northern
Europeans. TFR2 gene is relatively large, spanning 21 kb and
including 18 exons, thus, detection of new TFR2 mutations in
single patients remains cumbersome. Analysis of TfR2 muta-
tions should be especially considered in individuals with adult
non-HFE hemochromatosis, particularly from families with high
consanguinity. Although clinical descriptions of TfR2-related
hemochromatosis are currently limited, patients with TfR2
mutations almost invariably present signs of significant hepatic
iron overload and express a systemic iron loading syndrome
almost indistinguishable from that of HFE hemochromatosis.
The juvenile form of hemochromatosis is rare. Most cases are
due to mutations of HJV located on chromosome 1 [10]. In this
study 12 families were found to be homozygous or compound
heterozygous for six mutations inHJV. To date 23 mutations have
been identified in 43 juvenile hemochromatosis families. Oneconsequences of its genetic disruption. (A) In normal subjects, hepcidin secreted
cytes. HFE, TfR2 and HJVare likely required for hepcidin activation in response
ricted release of iron from macrophages and enterocytes followed by progressive
for details). Depending on the role of the regulators in the control of hepcidin
hromatosis, panel B or TfR2-hemochromatosis, panel C) or massive (HJV-
nel E) will cause a dramatic circulatory and tissue iron overload at least similar to
cts lie at the other end of the hepcidin–ferroportin functional axis, impaired iron
) with relative circulatory iron deficiency, that is, the pathologic hallmark of the
Table 1
Hereditary iron overload disorders in humans
Disorder Affected gene
(symbol/location)
Known or postulated
gene product function
Mechanism for
cellular iron accumulation
I. Hereditary
hemochromatosis (HC)
Hemochromatosis gene (HFE/6p21.3) Interaction with transferrin receptor 1
Increased iron influx
Cofactor for hepcidin synthesis
Transferrin-receptor 2 (TfR2/7q22) Uptake of iron-bound transferrin
Cofactor for hepcidin synthesis
Hepcidin antimicrobial peptide (HAMP/19q13.1) Down-regulation of iron efflux from
macrophages, enterocytes, placenta
Hemojuvelin (HJV/1p21) Bone morphogenic protein (BMP)
coreceptor required for
hepcidin transcription
II. Ferroportin-associated
iron overload (Ferroportin disease)
Solute carrier family 40 (iron-regulated transporter),
member 1 (SLC40A1/2q32)
Iron export from cells
including macrophages,
intestine, placenta
Decreased iron efflux
III. Aceruloplasminemia Ceruloplasmin (CP/3q23–q25) Iron export from cells Decreased iron efflux
IV. A(hypo)transferrinemia Transferrin (Tf/3q21) Iron transport in the bloodstream Increased iron influx
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present in half of juvenile hemochromatosis families. A small
proportion of patients with the juvenile form of hemochromatosis
carries mutations in the gene encoding the iron regulatory peptide
hepcidin on chromosome 19q13 [9]. Because of the higher rate of
iron loading associated with this disorder (and possibly
differential tissue sensitivities to this massive toxic insult),
cardiomyopathy and endocrinopathy, including reduced glucose
tolerance, appear earlier than they do in adult hemochromatosis,
and death before the age of 30 is not uncommon.
5. The ferroportin disease
The ferroportin disease (Tables 1 and 2) is a hereditary iron
storage disease distinct from hemochromatosis. It is an auto-
somal dominant inherited disorder of iron metabolism which
causes progressive iron retention predominantly in reticuloen-
dothelial cells of the spleen and liver and is characterized by
steadily increase of serum ferritin, inappropriately high as com-
pared to the extent of serum transferrin saturation, marginal
anemia, and mild organ disease [16].
The disorder was described clinically in 1999 [73] and
associated with the A77D mutation of ferroportin (FPN) in 2001
[11,12]. The ferroportin disease has been now reported in many
countries and, at variance with the distribution of the HFE gene
mutations that appear to be restricted to Caucasians of northern
European ancestry, it appears to be spread worldwide in
different ethnic groups [16].
A current pathogenic model for the ferroportin disease is that
loss-of-function mutations of FPN cause a mild but significant
impairment of iron recycling particularly by reticuloendothelial
macrophages [11], which normally must process and release a
large quantity of iron derived from the lysis of senescent
erythrocytes (Fig. 2F). The FPN defect may not be limiting for
iron transport in the enterocyte which handles relatively lowamount of iron on a daily basis: therefore, a sufficient iron
transport may be still guaranteed by the residual PFN protein
activity. In fact, absorbing enterocytes do not show excess iron
deposits in the ferroportin disease [74]. As a consequence, iron
retention by macrophages leads to tissue iron accumulation (i.e.
high serum ferritin) and decreased availability of iron for
circulating transferrin (i.e. low transferrin saturation) and for
bone marrow. At later stages, both iron retention in cells and
activation of feedback mechanisms to increase intestinal
absorption might contribute to more pronounced iron overload.
This pathophysiologic model is consistent with the finding that
patients with mutations in FPN have much larger reticuloen-
dothelial iron stores than patients with hemochromatosis.
Although the patients are not anemic in the adulthood,
indicating that adequate iron is available for normal erythropoi-
esis, they may show a reduced tolerance to phlebotomy and
become anemic on therapy in spite of persistently elevated
serum ferritin values [11,73] (Table 1). It is possible that
different mutations along the protein may differently affect the
function of FPN and indirectly lead to variability in clinical
expressivity. In this context, anecdotal evidence suggests that
mutation of this gene can also be associated with parenchymal
iron overload that closely resembles that of HFE-related
hemochromatosis [75]. In addition, recent in vitro studies
suggest that a subgroup of ferroportin mutations might lead to
hepcidin “resistance” and increased rather than diminished iron
export [76–78]. Therefore, a subgroup of patients with
ferroportin disease may carry gain-of-function mutations that
lead to enhanced iron release from enterocytes and macro-
phages and a phenotype similar to classic hemochromatosis.
This hypothesis cannot be ruled out a priori, but it awaits
validation from additional experimental data and more ex-
tensive clinical studies. Differential diagnosis should also con-
sider the rare form of familial hyperferritinemia-congenital
cataract syndrome, which is not associated with tissue iron
Genetic trait Epidemiology Clinical onset (decades) Main clinical manifestation Clinical course
Autosomal recessive
Affects Caucasians of northern European descent
4°–5° Liver disease Mild
Highly prevalent
Rare
Rare 2°–3° Endocrine and cardiac disease Severe
Autosomal dominant
Rare
Present in different ethnic groups worldwide 4°–5° Liver disease Marginal anemia Mild
Autosomal recessive Extremely rare 2°–3° Neurologic manifestations Severe
Autosomal recessive Extremely rare 1°–2° Anemia Severe
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clinically dominated by neurological disorders.
6. Conclusions and perspectives
The basic features of the hemochromatosis syndrome, as we
recognize it today, can be produced by pathogenic mutations of
at least four different iron metabolism genes. Since the common
pathogenic denominator of all forms of hemochromatosis is the
uncontrolled expansion of the plasma iron pool, mutations inTable 2
Iron overload disorders in humans
Hereditary
Hereditary hemochromatosis (HFE-, TfR2-, HJ-V, HAMP-related)
Ferroportin disease
Aceruloplasminemia
Atransferrinemia
H-ferritin related iron overload
Hereditary iron-loading anaemias
Acquired
Dietary
Parental
Long-term haemodialysis
Acquired iron loading anemias
Chronic liver disease
Hepatitis C and B
Alcoholic cirrhosis,
NASH
Porphyria cutanea tarda
Post portacaval shunting
Dysmetabolic iron overload syndrome
Miscellaneous
African siderosis
Neonatal haemochromatosisother known or unknown genes affecting this iron compartment,
may very well lead to the same syndrome. Depending on the
gene involved, and its physiological role in iron homeostasis, the
phenotype of hemochromatosis varies, ranging from massive
early-onset iron loading with severe organ disease (e.g.,
associated with homozygous mutations of HAMP or HJV) to
the milder late-onset phenotype characterizing classic HFE and
TfR2-related forms. Phenotypes on the latter end of the spectrum
are also particularly subject to the modifying effects of host-
related and environmental factors, such as dietary iron, alcohol
consumptions, viral hepatitis [16]. “Intermediate phenotypes”
could result from combined heterozygous or homozygous
mutations of multiple hemochromatosis genes, such as HAMP
and HFE [14]. In short, regardless of the underlying gene mu-
tations, hemochromatosis should be considered as a unique
syndrome with a phenotypic continuum [7]. With the notable
exception of hepcidin, the precise function for all other hemo-
chromatosis proteins is still unclear. Therefore, the actual chal-
lenge is now to dissect the molecular pathways underlying
transcriptional response of hepcidin to circulatory iron and un-
derstand, for instance, the dominant contribution to HJV1 or the
marginal role of HFE in this context. The precise definition of
the pathophysiology of hemochromatosis will greatly help un-
derstanding phenotypic expressivity and better target diagnostic
and therapeutic strategies.1 A recent publication suggests a mechanism by which HJV mutations cause
hemochromatosis. Babbit et al. [83] have shown that hemojuvelin is a bone
morphogenetic+protein (BMP) coreceptor: BMP upregulates hepatocyte
hepcidin expression through Smads, while hemojuvelin mutants associated
with hemochromatosis have impaired BMP signaling ability. This imply that in
juvenile hemochromathosis patients carrying HJV mutations+hemojuvelin
dysfunction decreases BMP signaling, thereby lowering hepcidin expression
and causing unrestricted iron transfer from macrophages and intestine into the
bloodstream.
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